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ABSTRACT 
The  p53  tumor  suppressor  gene  is  the  most  commonly  mutated  gene  in  cancer.  In  breast  cancer,  the 
presence of p53 gene alterations has been associated with worse prognosis. This study was attempted to 
associate p53 gene  mutations  with its protein expression  in North Eastern Indian population. We  used 
single-stranded conformation polymorphism to screen samples  for mutations in five  conserved regions, 
exons 4, 5, 6, 7 and 8, of the p53 gene. Mutations were confirmed by direct DNA sequencing. Samples were 
also analyzed for expression of p53 immunohistochemically. We found two critical mutations in the exon 4. 
A well known missense mutation at codon 72 (pro to arg) with a frequency of 47% was found which was 
significantly correlated with the immunohistochemical analysis of p53 protein in such patients. A novel 
nonsense mutation at codon 107 which leads to stop codon was also found. Although the occurrence of this 
mutation was very less, we did not find expression of p53 protein immunohistochemicaly. We support that 
mutation in p53 gene can be exploited as a prognostic marker for the early diagnosis of breast cancer, 
although more clinical and epidemiological data is required to establish this claim. 
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1. INTRODUCTION 
  In the light of the existing literature breast cancer is 
the  most  prevalent  cancer  among  women  and  affects 
approximately  1  million  women  worldwide  each  year 
comprising  18%  of  all  female  cancers  (Baum,  2002). 
Several  epidemiological  studies  have  documented 
extensively for the incidence of breast cancer in Indian 
scenario  (Badwe  et  al.,  1990;  Jussawalla  et  al.,  1980; 
1985;  1998;  Kapoor  et  al.,  1993).  One  in  fifty  eight 
women are affected by breast cancer in the age group of 
30-70 years and are mainly seen in the urban areas. The 
well  established  epidemiological  risk  factors  for  the 
development of the breast cancer are age at diagnosis, 
family  history,  parity,  age  at  the  menarche  and 
menopause,  diet,  socioeconomic  status,  history  of 
exposure to radiation and use of oral contraceptive pills 
(Helmrich et al., 2009; Dupont and Page, 1985). 
  In  the  last  decade  several  lines  of  evidence  have 
correlated  a  significant  association  between  the 
polymorphism of p53 gene and development of breast 
cancer  (Lacroix  et  al.,  2006).  p53  plays  a  key  role  in Shinjini Singh et al. / American Journal of Biochemistry and Biotechnology 9 (4): 395-403, 2013 
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mediating  cell  response  to  various  stresses,  mainly  by 
inducing  or  repressing  a  number  of  genes  involved  in 
cell cycle arrest, senescence, apoptosis, DNA repair and 
angiogenesis. The qualitative and quantitative activity of 
p53 depends on its integrity (mutation status), its amount 
and its specific post-translational modifications induced 
by the activation of the different stress-induced signaling 
pathways (Lacroix et al., 2006). This leads to variable 
patterns  of  association  between  p53  and  a  number  of 
other  co-regulatory  proteins,  of  which  some  may  be 
tissue-or  cell  type-specific.  Several  association  studies 
between  the  p53  expression,  polymorphism  and 
development of breast cancer have been carried out in 
various  geographical  regions  of  India  like  Bombay, 
Eastern  Rajasthan,  Aligarh,  Bangalore,  Jammu,  Surat 
and  Chennai  (Jussawalla  et  al.,  1998;  Kapoor  et  al., 
1993;  Sharma  et  al.,  1994;  Hussain  et  al.,  1994; 
Nandakumar et al., 1995; Gadhia et al., 1995; Juneja et al., 
1990;  Lin  et  al.,  2001;  Nayak  and  Das,  1997;  1999a; 
1999b;  Nayak  et  al.,  1996;  1998;  Kannan  et  al.,  2000; 
Keasri et al., 1997), In continuation, the present study was 
designed  to  explore  three  specific  issues  of  p53  in  the 
subjects suffering from Invasive Ductal Carcinoma (IDC) 
of breast among middle North-Eastern Indian population: 
(a) Does the exonic region of p53 contain any sequence 
aberration?  (b).  Is  there  any  correlation  between  the 
mutational analysis of p53 with clinico-pathological data of 
the subjects? (c) Is there any correlation between the p53 
mutation (if any) with expression status of p53 protein?  
2. MATERIALS AND METHODS 
2.1. Subject Selection 
  A  total  of  62  (58  females  and  4  males)  fresh 
excision  biopsies  were  obtained  from  the  patients  of 
Invasive  Ductal  Carcinoma  with  the  mean  age  of 
53.35±9.29  years  (aged  between  33  to  75).  All  the 
patients  included  in  the  present  study  were  recruited 
from in patient department of Cancer Research Institute, 
North  Eastern  Railways,  Lehertara,  Varanasi,  India, 
between  January  2009  to  March  2010  with  their  prior 
informed consent and their detailed history was obtained. 
Patients receiving chemotherapy and radiotherapy were 
excluded  from  the  study.  Study  was  approved  by  the 
institutional ethical committee. 
2.2. Sample Collection 
  Tumor  biopsies  were  collected  directly  from  the 
surgical operation theater of the department of oncology in 
chilled phosphate-buffered saline  from the patients  who 
underwent  mastectomy.  Each  freshly  microdissected 
tumor  was divided into two equal portions by use of a 
disposable  scalpel.  Slices  were  taken  from  the  outer, 
viable, cellular region of one half for later DNA analysis 
and sequencing. Corresponding slices from the other half 
taken in 10% formalin were prepared for histopathological 
examination. The part of the tumor that was frozen was 
stored at -80°C until analysis. The adjacent tissue biopsy 
from each individual was taken as control. 
2.3. DNA Isolation 
  Cellular DNA from collected breast tumor biopsies 
was  isolated  using  standard  proteinase  K  digestion, 
phenol-chloroform  extraction  and  ethanol  precipitation 
method  routinely  being  used  in  our  laboratory 
(Sambrook  and  Russell,  2001).  The  quality  and 
concentration  of  DNA  was  measured  on  an  ethidium 
bromide-stained  1%  agarose  gel  and  by  standard 
spectrophotometric methods. 
2.4. Polymerase Chain Reaction 
  Approximately, 100-200 ng DNA was utilized for 
conventional PCR using the protocol routinely followed 
in our laboratory. Briefly, the method involved a 50  L 
reaction mix containing 100-200 ng DNA, 5.0 µL of 
10X PCR buffer, 3.0 µL of 25 Mm MgCl2, 0.5 µL of 
10 Mm dNTPs, 0.5 µL of 10 pmol forward primer, 0.5 
µL  of  10  pmol  reverse  primer,  0.5  µL  of  Taq  DNA 
polymerase  (1  U  µL
-1). The  PCR  primers  for  exonic 
regions (4 to 8) of p53 used for amplification have been 
mentioned in Table 1.  
2.5. Single-Strand  Conformation  Polymorphism 
Analysis 
  Single-Strand  Conformation  Polymorphism  (SSCP) 
analysis was performed as described by Michaelides et al. 
(1995).  Depending  on  the  PCR  product  concentration, 
4±1.2  mL  of  the  PCR  product  was  added  to  the  same 
volume  of  denaturing  solution  containing  800  mL 
formamide, 100 mL of 1% Bromophenol Blue, 100 mL of 
1% xylene cyanol, 2 mL of 0.5 M EDTA and 1 mL of 10 
M NaOH per 1 mL solution. Samples were denatured at 
93°C  for  5  min  and  transferred  immediately  to  ice  to 
prevent renaturation of DNA. Each sample was loaded 
onto a 10% polyacrylamide gel with 0.5 mm thickness. 
Electrophoresis was performed in 1X TBE at 4°C and at 
19 mA for 5 to 7 h depending on the size of the PCR 
product. Each PCR product was electrophoresed at least 
three  times  to  increase  precision  and  to  prevent  false 
positive  results.  Bands  were  visualized  after  silver 
staining of gel, as described (Bourn et al., 1994). Shinjini Singh et al. / American Journal of Biochemistry and Biotechnology 9 (4): 395-403, 2013 
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Table 1. Primers used in amplification of exons 4 to 8 of p53 gene 
  Primer sequence 
p53 Exon  F = Forward Primer, R = Reverse primer 
4  F   TGACTGCTCTTTTCACCCAT 
  R   GGAAGCCAGCCCCTCAGGGC 
5  F   TGTTCACTTGTGCCCTGACT 
  R   CAGCCCTGTCGTCTCTCCAG 
6  F    GCCTCTGATTCCTCACTGAT 
  R    TTAACCCCTCCTCCCAGAGA 
7  F    ACTGGCCTCATCTTGGGCCT 
  R   TGTGCAGGGTGGCAAGTGGC 
8  F    TAAATGGGACAGGTAGGACC 
  R    TCCACCGCTTCTTGTCCTGC 
 
2.6. Sequencing 
  Purified  PCR  products  of  the  samples  showing 
mobility  shift  on  SSCP  analysis  and  randomly  chosen 
samples  were  sent  for  sequencing.  Direct  DNA 
sequencing  using  an  automated  ABI  3100  Genetic 
Analyzer (Bangalore Genei) using ABI’s AmpliTaq FS 
dye terminator cycle sanger’s sequencing chemistry. 
2.7. Sample Processing for Histology and Analysis 
  Paraffin-embedded tumor sections on poly-L-lysine 
coated slides were dewaxed in xylene and rehydrated in 
ethanol  and  distilled  water.  Antigen  retrieval  in  a 
microwave  oven  at  750W  (two  cycles  for  10  minutes 
each) enhanced p53 antigen accessibility to antibodies. 
The expression of Estrogen Receptor (ER), Progesterone 
Receptor  (PR)  and  HER2  (Human  Epidermal  growth 
factor  Receptor-2)  were  also  checked  using  specific 
antibodies.  Positive  p53  IHC  staining  was  seen  in  the 
nucleus of cancer cells. IHC-positive samples were sub-
classified  with  regard  to  immunostaining  intensity  and 
extent according to graded scales that ranged from 1 to 3. 
Allred’s method was used for the scoring of p53, ER and 
PR and for HER2 expression, Hercep Test; DAKO was 
used  (Allred  et  al.,  1990;  Dako  and  Hoffman,  2002). 
Super  sensitive  polymer-HRP  detection  system  and 
primary  antibodies  p53,  ER,  PR  and  HER2  from 
Biogenex, CA, USA were used. All slides were viewed 
and judged microscopically by the pathologist. 
2.8. Statistical Analysis 
  Analysis was performed with the Statistical Package 
for  Social  Science  (SPSS)  windows  version  16.  Chi-
square  test  was  used  to  compare  the  frequencies. 
Statistical significance was considered when p≤0.05. 
3. RESULTS 
  Clinico-pathological  features  of  the  recruited 
patients are presented in Table 2. Most of the patients at 
diagnosis  were  either  in  tumor  stage  II  (75.1%)  or  in 
stage III (24.1%). All patients underwent mastectomy.  
  Sequencing of amplified p53 exons (4 to 8) from all 
the  recruited  subjects  were  carried  out  to  confirm  the 
mobility shift bands detected on SSCP  gel. Out of 62 
patients, we found 29 subjects with p53 mutations. Table 
3 summarizes the age  wise frequency of patients  with 
and  without  p53  mutations.  We  found  2  critical 
mutations in the exon 4 at codon positions 72 and 107 
resulting  in  the  missense  and  nonsense  mutations, 
respectively (Fig. 1) as compared to the corresponding 
controls.  Table  4  represents  a  summary  of  p53  gene 
mutations  in  breast  cancer  patients.  No  sequence 
aberration  was  found  in  exons  5,  6,  7  and  8  in  the 
patients  with  respect  to  their  corresponding  control 
biopsies. The sequencing results were further confirmed 
by  Single-strand  conformation  polymorphism  analysis 
also  (Fig.  2).  The  nonsense  mutation  at  codon  107 
occurred along with the missense one at codon 72. To 
search  for  suitable  mutations  of  p53  gene  PCR-SSCP 
analysis was used as a screening technique.  
  All  the  mutated  and  wild  type  sequences  were 
submitted to NCBI and the accession numbers obtained 
were  as  follows:  exon  4  (wild  type):  BankIt1451832 
Seq1  JF923567,  exon  4  (mutation  A):  BankIt1451832 
Seq2  JF923568,  exon  4  (mutation  B):  BankIt1451832 
Seq3 JF923569, exon 5: BankIt1451832 Seq4 JF923570, 
exon  6:  BankIt1451832  Seq5  JF923571,  exon  7: 
BankIt1451832  Seq6  JF923572  and  exon  8: 
BankIt1451832 Seq7 JF923573. 
  Table 5 summarizes the frequency of p53 mutation 
positive  patients  and  their  clinicopathological  features. 
Menopausal status (p = 0.013), histological grade (p = 
0.048) and axillary lymph node involvement (p = 0.018) 
were found to be significantly associated with the p53 
mutation positive cases. 
  Out of 62 biopsies from patients, 27 were found to 
be  p53  positive,  further  immunohistochemical  analysis 
revealed a significant higher expression of p53 protein in 
the  breast  cancer  biopsies  as  compared  to  their 
corresponding  control  biopsies  (Fig.  3).  A  total  of  51 
(82.0%) tumors were found negative for ER, 54 (87.0%) 
tumors were found negative for PR and 44 (71.0%) were 
found  positive  for  HER2  membrane  staining. 
Interestingly we did not find the expression of p53 in the 2 
patients having nonsense mutation. Table 6 summarizes 
the age wise frequency of patients with p53 expression. 
Correlation of menstrual status with p53 expression and 
HER2  expression  was  found  to  be  significant,  their  p 
values  being  0.031  and  <0.001,  respectively.Shinjini Singh et al. / American Journal of Biochemistry and Biotechnology 9 (4): 395-403, 2013 
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Fig. 1. Immunohistochemical staining of ER(1a), PR(1b) and HER2(1c) at 400X 
 
 
 
Fig. 2. Representative partial electropherograms of sequencing results showing two critical mutations in the exon 4 of p53 gene 
 
 
 
Fig. 3. Detection of mutations in exon 4 of p53 gene. 10% polyacrylamide gel picture showing the electrophoretic mobility shift of p53 
exon 4 from various tumor biopsies as compared to their normal biopsies. Samples 1, 2 and 4 are showing the genetic aberration Shinjini Singh et al. / American Journal of Biochemistry and Biotechnology 9 (4): 395-403, 2013 
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Table 2. Clinicopathological features of the breast cancer patients 
----------------------------------------------Parameters-----------------------------------------  N [Value (%)] 
Breast Side  Left  32/62 (51.6) 
  Right  30/62 (48.3) 
Menstrual Status  Pre menopausal  18/58 (31.0) 
  Post menopausal  40/58 (68.9) 
Age at menarche  ≤13 years  22/58 (37.9) 
  >13 years  34/58 (58.6) 
Parity  Nulliparous  9/58 (15.5) 
  1-4 Children  35/58 (60.3) 
  >4 children  14/58 (24.1) 
Lifetime duration  <36 months  24/58 (41.3) 
of breast feeding  36-54 months  12/58 (20.6) 
  55-78 months  10/58 (17.2) 
  >78 months  12/58 (20.6) 
Pagets`s Disease  Yes  4/62 (6.4) 
  No  58/62 (93.5) 
Tumor Stage  T2  0/62 (0) 
  T3  36/62 (58.0) 
  T4  26/62 (41.9) 
Histological Grade  Grade I  0/62 (0) 
  Grade II  47/62 (75.8) 
  Grade III  15/62 (24.1) 
No. of Axillary  0  18/62 (12.9) 
Lymph Nodes  1-3  27/62 (43.5) 
  >3  17/62 (27.4) 
 
Table 3. Summary of p53 mutations in breast cancer patients 
  p53 Positive    p53 Negative 
  -------------------------------------------------  -------------------------------------------------- 
Age (years)  Number  Percentage  Number  Percentage 
≤50  11/62  17.7  16/62  25.8 
>50  18/62  29.0  17/62  27.4 
 
Table 4. Nature of p53 mutations in sporadic breast cancer patients 
  Exon containing   Codon  Nucleotide    Amino Acid  Types of 
No. of patients  mutation  Number  Number  Base Change  Change  mutation 
29  4  72  1138  CCC→CGC  Pro→Arg  Missense 
2  4  107  1149  TAC→TAG  Tyr→Stop  Nonsense 
 
Table 5. Patients’ characteristics and clinic pathological features of p53 mutants. 
----------------------------------Clinical features----------------------------------  p53 mutants   n (%) 
Age (years)  ≤50  11/29 (37.9) 
  >50  18/29 (62.0) 
Residence  Rural  2/29 (6.8) 
  Urban  27/29 (51.7) 
Menopausal Status  Pre  11/25 (44.0) 
  Post  18/25 (72.0) 
Breast involved  Right  10/29 (34.4) 
  Left  19/29 (65.5) 
Provisional Diagnosis  IDC  29/29 (100) 
  Paget`s disease  2/29 (6.8) 
Lymph Nodes involved  Yes  19/29 (65.5) 
  No  10/29 (34.4) 
Histological Grade  Grade I  0 (0) 
  Grade II  22/29 (75.8) 
  Grade III  7/29 (24.1) 
Clinical Tumor Stage  T2  0 (0) 
  T3  17/29 (58.6) 
  T4  12/29 (41.3) Shinjini Singh et al. / American Journal of Biochemistry and Biotechnology 9 (4): 395-403, 2013 
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Table 6. Summary of the age wise frequency of patients with p53 expression 
  p53 IHC status 
  ----------------------------------------------------------------------------------------------------------------------------------- 
Age (years)  Negative [n (%)]  +1 [n (%)]  +2[n (%)]  +3[n (%)] 
≤ 50  16/62 (25.8)  0/62 (0)  1/62 (1.6)  9/62 (14.5) 
>50  3/62 (4.8)  9/62 (14.5)  1/62 (1.6)  18/62 (29.0) 
 
Tumor size was found to be significantly associated with 
ER negativity (p = 0.015), histological grade was found 
to be significantly associated with p53 expression (p = 
0.018)  and  ALN  involvement  was  also  found  to  be 
significantly associated with p53 expression (0.025). 
4. DISCUSSION 
  p53, a well established tumor suppressor gene has 
the centre of attraction for the researchers in the field 
of  cancer  biology  for  its  ability  to  regulate  several 
fundamental cellular processes like cell cycle arrest, 
senescence,  apoptosis,  DNA  repair  and  angiogenesis 
(Lacroix  et  al.,  2006).  The  status  of  p53  in  human 
breast  cancer  has  been  the  subject  of  intensive 
investigation  (Gasco  et  al.,  2002;  Anne-Lise,  2003). 
The  presence  of  mutation,  with  or  without 
accompanying Loss of Heterozygosity (LOH), was an 
early finding in cell lines and primary breast cancers, 
establishing p53 as a bona-fide tumor suppressor gene 
in  the  breast.  Epidemiological  studies  have 
documented extensively the incidence of breast cancer 
in the western population (Ursin et al., 1994) but the 
available  information  in  India  is  limited.  India  is  a 
vast  sub-continent  with  a  huge  population  of 
multiracial  society  with  widely  varying  cultures  and 
several  ethnic  groups.  Different  aspects  of  breast 
cancer  involving  epidemiology,  risk  factors  and 
susceptibility have been dealt in various communities 
and regions. Some association studies between the p53 
expression, polymorphism and development of breast 
cancer have been carried out in various geographical 
regions  of  India  like  Bombay,  Eastern  Rajasthan, 
Aligarh,  Bangalore,  Jammu,  Surat,  Chennai 
(Jussawalla  et  al.,  1998;  Kapoor  et  al.,  1993;    
Sharma  et  al.,  1994;  Hussain  et  al.,  1994; 
Nandakumar  et  al.,  1995;  Gadhia  et  al.,  1995;    
Juneja et al., 1990; Lin et al., 2001; Nayak and Das, 
1997;  1999a;  1999b;  Nayak  et  al.,  1996;  1998; 
Kannan et al., 2000; Keasri et al., 1997). The present 
study is an extension of these Indian studies for the 
geographically  distinct  middle  north  eastern 
population in order to explore the sequence aberration 
in  p53  gene  and  its  protein  expression  as  well  as 
correlation with demographic and clinical findings. 
  Our  study  comprised  of  62  subjects  with 
confirmed diagnosis of IDC of breast. Association of 
the  p53  mutation  was  found  significant  with  gender 
postmenopausal  status,  histological  grade  and  ALN 
involvement which was consistent with existing data 
in the literature (Giordano et al., 2004; Cutler et al., 
2009;  Madigan  et  al.,  1995).  Our  sequencing  data 
revealed  p53  gene  mutations  in  29  (47%)  tumor 
biopsies from different individuals. We observed two 
critical mutations in the exonic region 4 of p53 (Fig. 2 
and  3).  The  missense  mutation  at  codon  72  (pro  to 
Arg)  has  been  shown  to  have  varying  ethnic  and 
geographical  distribution  (Chosdol  et  al.,  2002;   
Ihsan et al., 2011; Kalemi et al., 2005). The frequency 
of this mutation in our breast cancer population was 
found to be around 50%. It has already been reported 
that  the  p53  Arg  homozygous  genotype  could  be  a 
potential genetic risk factor for cancer (Buyru et al., 
2003;  Papadakis  et  al.,  2000).  Further  our  mutation 
data  was  correlated  with  the  immunohistochemical 
analysis of significant high expression of p53 protein 
(Fig.  4).  In  healthy  humans,  the  p53  protein  is 
continually  produced  and  degraded  in  the  cell.  The 
degradation  of  the  p53  protein  is  associated  with 
MDM2 binding. In a negative feedback loop, MDM2 
is  itself  induced  by  the  p53  protein  (Haupt  et  al., 
1997).  However,  mutant  p53  protein  often  does  not 
induce MDM2 and is thus able to accumulate at very 
high  concentrations  (Peng  et  al.,  2001)  and  hence 
detectable  by  IHC.  We  reported  another  novel 
nonsense  mutation  at  codon  107  which  leads  to  the 
stop codon. Although the occurrence of this mutation 
is  very  less,  but  interestingly  we  did  not  find  the 
expression  the  p53  protein  by  histological  analysis 
which  supports  the  translation  of  truncated  p53 
protein  and  ultimately  leads  to  protein  degradation 
(Heck et al., 2010).  Shinjini Singh et al. / American Journal of Biochemistry and Biotechnology 9 (4): 395-403, 2013 
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Fig. 4. Immunostaining showing p53 positivity at 400X 
 
5. CONCLUSION 
  Our  data  thus  indicate  that  p53  gene  can  be 
exploited as a prognostic marker for the early diagnosis 
of  breast  cancer,  although  more  clinical  and 
epidemiological  data  across  the  Indian  and  Asian 
geographical regions is required to establish this claim.  
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